--- title: "Precision Neuroscience's $250M Round: What It Means to 'Own the Supply Chain' for Brain Implants" slug: precision-neuroscience-series-d-bci-2026 category: tech category_label: "Tech" author: "BrainWavePost Staff" date: 2026-10-02 tags: ["brain-computer interface", "BCI", "Precision Neuroscience", "neurotech", "MEMS", "Layer 7", "funding", "Medtronic"] read_time_minutes: 8 canonical_url: https://brainwavepost.com/article/precision-neuroscience-series-d-bci-2026 source: BrainWavePost --- # Precision Neuroscience's $250M Round: What It Means to 'Own the Supply Chain' for Brain Implants *Tech · 2026-10-02 · BrainWavePost Staff · 8 min read* > Precision Neuroscience closed an oversubscribed $250M Series D and now runs its own MEMS factory in Texas to build its brain-implant electrodes end to end. Here is a sourced look at what the money buys, what its device can and can't do today, and why in-house manufacturing matters for neurotech. > **The short version** _(note)_ > > This is a funding-and-manufacturing milestone, not a medical breakthrough. Precision's surface electrode array is FDA-cleared only for temporary use (up to 30 days), its long-term implantable product is still in development, and no BCI is an approved consumer device. The new factory is about controlling how the hardware is made, not about a new clinical result. [1][2][3] Precision Neuroscience — a brain-computer interface (BCI) company co-founded by Benjamin Rapoport, who also co-founded Neuralink — has closed an oversubscribed $250 million Series D financing round. The round was co-led by Pershing Square Capital Management, The Ackman Oxman Institute, and a life-sciences investment fund, and brings the company's total raised since its 2021 founding to roughly $430 million. [1][2] - **$250M** — oversubscribed Series D round [1][2] - **~$430M** — total raised since the 2021 founding [1][2] - **1,024** — microelectrodes on the Layer 7 thin-film array [3][4] - **≤30 days** — FDA-cleared implantation duration (temporary use) [3] ## What the company actually makes Precision's device is the Layer 7 Cortical Interface: a flexible, thin-film microelectrode array that rests on the surface of the brain rather than penetrating it. The array is about one-fifth the thickness of a human hair and carries 1,024 microelectrodes, giving it far higher spatial resolution than conventional clinical electrode grids. [3][4] Because it sits on the cortical surface, the company frames it as 'minimally invasive' relative to penetrating implants — though placing it still requires neurosurgery. [4] In 2025 the device received FDA 510(k) clearance to record, monitor and stimulate on the brain's surface for implantation durations of up to 30 days. [3] That is a meaningful regulatory step, but it is a clearance for temporary use of a component — not an approval of a permanent, implanted BCI product, and not a therapy with its own proven clinical outcome. [3] > **Read the FDA clearance carefully** _(note)_ > > A 510(k) clearance means the FDA agreed the device is substantially equivalent to existing legally marketed devices for a defined use — here, temporary (up to 30-day) surface recording, monitoring and stimulation. It is not the same as approval of a long-term implant or of a specific treatment claim. The permanent version of the system remains in development. [3] ## The real news: bringing manufacturing in-house The headline figure is the money, but the strategically interesting part is what Precision is doing with it. The company has built a wholly owned micro-electromechanical systems (MEMS) manufacturing facility in Texas, giving it end-to-end control over production of its electrode arrays rather than depending on outside foundries. [1][2] MEMS fabrication — the same broad family of micro-fabrication used for chip sensors — is how these hair-thin arrays with over a thousand electrodes are made. For a medical-device company, owning that line matters for a few concrete reasons: - Supply control: specialized microfabrication is normally outsourced to a handful of foundries; an in-house line reduces dependence on their timelines and priorities. - Iteration speed: designing and building arrays under one roof shortens the loop between a design change and a testable part. - Quality and regulatory traceability: medical devices need tightly documented, reproducible manufacturing, which is easier to guarantee when you run the process yourself. - Scale: moving from hand-built research quantities toward commercial volumes is itself an engineering problem, separate from whether the device works. This is what the original framing means by moving 'closer to commercial hardware viability': the bet is that controlling manufacturing is a prerequisite for ever shipping a BCI at scale. It is a claim about industrial readiness, not about a new medical capability. [1][2] ## Where it is in the clinic Precision has reported that its technology has been used in more than 100 patient procedures across 18 medical institutions — generally short-term intraoperative or temporary-placement research use rather than long-term implants in people living with the device. [1] In January 2026 the company announced a partnership with Medtronic to pair the Layer 7 interface with Medtronic's StealthStation surgical navigation platform, aimed at integrating the array into existing neurosurgical workflows. [5] ## What this does and doesn't tell us - It does show strong investor conviction and a serious move toward manufacturing at scale. [1][2] - It does not mean a permanent brain implant is FDA-approved — current clearance is for temporary (≤30-day) use. [3] - It does not report any new clinical outcome; a funding round is not a trial result. [1] - BCIs remain investigational for the chronic, restorative uses (restoring speech or movement) that draw the most attention; those are goals, not delivered products. [3][4] The honest summary: Precision Neuroscience raised a large, oversubscribed round and is internalizing the hard, unglamorous work of making its electrodes. That is a credible step toward a commercial BCI — but the device is cleared only for temporary use today, the long-term implant is still being developed, and the biggest therapeutic promises of BCIs remain unproven. [1][3][4] > **Editorial note** _(tip)_ > > This is technology and business journalism, not investment or medical advice. Funding figures and the device details above reflect the company's announcements and FDA records as reported; they are not a prediction that any product will reach market or work as hoped. ## Sources and further reading - [1] MassDevice — 'Precision Neuroscience raises $250M in Series D for its BCI' (2026): https://www.massdevice.com/precision-neuroscience-raises-250m-in-series-d-for-its-bci/ - [2] MedTech Dive — 'Precision Neuroscience raises $250M for brain-computer interface work' (2026): https://www.medtechdive.com/news/precision-neuroscience-raises-250m-for-brain-computer-interface-work/831344/ - [3] Medscape / Fierce Biotech — FDA 510(k) clearance of the Layer 7 Cortical Interface for temporary (up to 30-day) surface recording, monitoring and stimulation (2025): https://www.fiercebiotech.com/medtech/fda-clears-precision-neurosciences-minimally-invasive-brain-computer-interface-implant - [4] Wikipedia — 'Precision Neuroscience' (overview of the Layer 7 array: thin-film, ~1/5 hair thickness, 1,024 microelectrodes): https://en.wikipedia.org/wiki/Precision_Neuroscience - [5] MassDevice — 'Precision Neuroscience, Medtronic partner on BCI tech' (2026): https://www.massdevice.com/precision-neuroscience-medtronic-partner-on-bci-tech/ --- _Canonical article: [https://brainwavepost.com/article/precision-neuroscience-series-d-bci-2026](https://brainwavepost.com/article/precision-neuroscience-series-d-bci-2026) — © BrainWavePost. Educational content; see the article page for full disclaimers._